Sumitomo Pharma Co., Ltd. (DNPUF)

Sumitomo Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	445,205	398,832	314,558	555,544	560,035	515,952
Revenue Growth (YoY)	29.92%	26.79%	-43.38%	-0.80%	8.54%	6.88%
Cost of Revenue	170,811	153,437	126,577	178,919	157,127	137,773
Gross Profit	274,394	245,395	187,981	376,625	402,908	378,179
Selling, General & Admin	167,170	160,386	397,705	339,212	217,339	173,666
Research & Development	41,117	49,865	112,637	131,858	94,903	132,682
Other Operating Expenses	-50,688	1,902	942	-2,200	-1,043	825
Operating Expenses	157,599	232,372	543,117	502,974	342,941	323,880
Operating Income	116,795	13,023	-355,136	-126,349	59,967	54,299
Interest Expense	-	-6,221	-3,893	-2,640	-2,970	-2,436
Interest & Investment Income	9,679	1,421	2,839	5,486	1,175	1,153
Earnings From Equity Investments	-341	-905	-	-	-	-
Currency Exchange Gain (Loss)	-	-4,942	32,829	26,308	24,530	8,037
Other Non Operating Income (Expenses)	-	-1,451	-30	-95	-8	-127
EBT Excluding Unusual Items	126,133	925	-323,391	-97,290	82,694	60,926
Gain (Loss) on Sale of Investments	-	13,537	-224	24,735	-	-
Gain (Loss) on Sale of Assets	16,686	3,149	501	24,635	267	16,925
Pretax Income	142,819	17,611	-323,114	-47,920	82,961	77,851
Income Tax Expense	-11,904	-6,024	-8,185	48,794	42,361	41,022
Earnings From Continuing Operations	154,723	23,635	-314,929	-96,714	40,600	36,829
Minority Interest in Earnings	-	-1	-40	22,202	15,813	19,390
Net Income	154,723	23,634	-314,969	-74,512	56,413	56,219
Net Income to Common	154,723	23,634	-314,969	-74,512	56,413	56,219
Net Income Growth	-	-	-	-	0.34%	37.95%
Shares Outstanding (Basic)	397	397	397	397	397	397
Shares Outstanding (Diluted)	397	397	397	397	397	397
EPS (Basic)	389.45	59.49	-792.79	-187.55	141.99	141.50
EPS (Diluted)	389.45	59.49	-792.79	-187.55	141.99	141.50
EPS Growth	-	-	-	-	0.34%	37.95%
Free Cash Flow	23,018	8,002	-252,664	3,470	23,892	129,553
Free Cash Flow Per Share	57.94	20.14	-635.97	8.73	60.14	326.09
Dividend Per Share	-	-	-	21.000	28.000	28.000
Dividend Growth	-	-	-	-25.00%	-	-
Gross Margin	61.63%	61.53%	59.76%	67.79%	71.94%	73.30%
Operating Margin	26.23%	3.26%	-112.90%	-22.74%	10.71%	10.52%
Profit Margin	34.75%	5.93%	-100.13%	-13.41%	10.07%	10.90%
Free Cash Flow Margin	5.17%	2.01%	-80.32%	0.63%	4.27%	25.11%
EBITDA	139,149	38,585	-317,371	-85,086	98,315	76,972
EBITDA Margin	31.25%	9.67%	-100.89%	-15.32%	17.55%	14.92%
D&A For EBITDA	22,354	25,562	37,765	41,263	38,348	22,673
EBIT	116,795	13,023	-355,136	-126,349	59,967	54,299
EBIT Margin	26.23%	3.26%	-112.90%	-22.74%	10.71%	10.52%
Effective Tax Rate	-	-	-	-	51.06%	52.69%
Advertising Expenses	-	25,000	42,372	59,857	37,780	37,362

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.